Clinical Research Directory
Browse clinical research sites, groups, and studies.
Randomized Comparison of Efficacy and Safety of High-intensity Rosuvastatin/Ezetimibe Combination Versus Treat-to-target Rosuvastatin Monotherapy for Patients With Peripheral Artery or Polyvascular Disease (CARE-PVD Trial)
Sponsor: Yonsei University
Summary
Patients with atherosclerotic peripheral artery disease often have combined coronary artery disease or cerebral artery disease and show high rates of cardiovascular mortality and morbidities. Therefore, secondary prevention for these patients is of great clinical importance. Currently, Korean, US, and European guidelines recommend different LDL cholesterol target goals in patients with peripheral artery disease. In recent clinical trials, combination therapy of statin plus ezetimibe demonstrated improved cardiovascular outcomes compared with statin monotherapy. Thus, the purpose of the CARE-PVD study is to investigate whether the combination therapy of high intensity rosuvastatin 20 mg plus ezetimibe 10 mg can improve cardiovascular outcomes in patient with peripheral artery disease or polyvascular artery disease in comparison with rosuvastatin treat-to-target (LDL cholesterol \<70 mg/dL) monotherapy.
Key Details
Gender
All
Age Range
19 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
2462
Start Date
2024-04-22
Completion Date
2029-05-06
Last Updated
2025-05-20
Healthy Volunteers
No
Interventions
Combination therapy of high-intensity dose rosuvastatin and ezetimibe
Combination therapy of rosuvastatin 20 mg and ezetimibe 10 mg
Rosuvastatin monotherapy for treat-to-target
Rosuvastatin monotherapy for treat-to-target (LDL cholesterol \<70 mg/dL)
Locations (1)
Division of Cardiology, Yonsei Cardiovascular Hospital, Yonsei University College of Medicine
Seoul, South Korea